CT-CIDRA-MINERALS
19.12.2022 10:01:39 CET | Business Wire | Press release
CiDRA Minerals Processing Inc. (“CiDRA”) and OZ Minerals Ltd (“OZ Minerals”) are pleased to announce that they have entered into a Memorandum of Understanding that provides a basis of common understanding to commission a Front End Engineering Design (FEED) study for customization and tie-in of CiDRA’s proprietary mineral separation technology for operation in a grind circuit rougher application at OZ Minerals’ Carrapateena Mine Site. At the same time, CiDRA and OZ Minerals have agreed to deploy a demonstration plant based on CiDRA’s technology at the site. CiDRA and OZ Minerals share a desire to increase the technology readiness level (TRL) for a commercial scale implementation of CiDRA’s technology as a grind circuit rougher which will process a coarse fraction of the primary grind hydrocyclone underflow at Carrapateena. The goals of the Partnership are to increase plant throughput, recovery, and net metal production at a reduced specific energy consumption in keeping with their efforts to help meet the world’s raw material needs in a responsible, equitable, and sustainable way.
“We are excited to take this next step in our relationship with OZ Minerals. Since early 2022, we have been working closely with the Carrapateena Mine Site to evaluate the potential benefits of CiDRA’s technology. This new technology enables a robust process that can recover mineral particles across a size range from ultra-fine to very coarse with high selectivity and minimal hydraulic entrainment. Applying CiDRA’s novel technology as a grind circuit rougher unlocks the concentrator’s throughput capacity while maintaining world class mineral recovery. The MOU will allow us to collectively focus our efforts to leverage this incredible innovation to enhance the net metal production of the Carrapateena Mine Site and create a tremendous value for each of our companies,” stated Paul Rothman, President of CiDRA.
Joe Seppelt, Manager-Processing at OZ Minerals’ Carrapateena Mine Site stated: “The CiDRA technology can enable us to increase our plant throughput without sacrificing the industry leading recoveries that we have been able to achieve at Carrapateena. This capital efficient approach has the potential to operate with less water and energy and with a smaller footprint. We look forward to working with CiDRA to realize the benefits of their innovation.”
About CiDRA Minerals Processing
CiDRA Minerals Processing develops advanced technologies and solutions that create new paradigms in the minerals processing industry with a focus on increasing enterprise value through optimization, increased recoveries and enhancing the sustainability of limited and valuable resources. CiDRA Minerals Processing provides measurement and control solutions to over 460 mine sites in 46 countries.
About OZ Minerals
At OZ Minerals we strive to be modern. We’re guided by our purpose, “Going beyond what’s possible to make lives better”. We believe that only when we create value for all our stakeholders will we be successful and sustainable. Our framework of systems and behaviours we call The OZWay, guides us while giving us the freedom and pathways to achieve our aspirations and purpose. We are passionate about creating an inclusive culture where people challenge, innovate, learn and grow together. By ethically and responsibly exploring for and mining copper we contribute to a low carbon future and economic wellbeing which, in turn, helps us achieve our purpose and contribute to a better future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release
- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 09:00:00 CEST | Press release
New One-Day Intensive Experience Offered 9 June Ahead of Conference 10-11 June at Tobacco Dock Featuring 10 Stages and 14 Tracks The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
